{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:01:13Z","timestamp":1783576873313,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100010355","name":"Hellenic Society of Medical Oncology","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100010355","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,8,24]]},"DOI":"10.1038\/s41416-025-03032-2","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T12:07:28Z","timestamp":1748002048000},"page":"353-364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of DNA damage response signals and oxidative stress status with nivolumab efficacy in patients with Head and Neck Squamous Cell Carcinoma"],"prefix":"10.1038","volume":"133","author":[{"given":"Christina","family":"Papanikolaou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Economopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-3661","authenticated-orcid":false,"given":"Aris","family":"Spathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Kotsantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Gavrielatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Anastasiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Moutafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Kyriazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George-Romanos P.","family":"Foukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis M.","family":"Lelegiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4397","authenticated-orcid":false,"given":"David","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Panayiotides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Foukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2945-1329","authenticated-orcid":false,"given":"Vassilis L.","family":"Souliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Psyrri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"3032_CR1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/0022034518772278","volume":"97","author":"JE Nor","year":"2018","unstructured":"Nor JE, Gutkind JS. Head and neck cancer in the new era of precision medicine. J Dent Res. 2018;97:601\u20132.","journal-title":"J Dent Res"},{"key":"3032_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.seminoncol.2017.06.007","volume":"44","author":"V Prasad","year":"2017","unstructured":"Prasad V, Kaestner V. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017;44:132\u20135.","journal-title":"Semin Oncol"},{"key":"3032_CR3","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.21037\/atm.2019.03.58","volume":"7","author":"JM Bauml","year":"2019","unstructured":"Bauml JM, Aggarwal C, Cohen RB. Immunotherapy for head and neck cancer: where are we now and where are we going? Ann Transl Med. 2019;7:S75.","journal-title":"Ann Transl Med"},{"key":"3032_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, Soulieres D, Tahara M, de Castro G Jr, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023;41:790\u2013802.","journal-title":"J Clin Oncol"},{"key":"3032_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179\u2013204.","journal-title":"Mol Cell"},{"key":"3032_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pharmthera.2015.06.011","volume":"154","author":"IS Pateras","year":"2015","unstructured":"Pateras IS, Havaki S, Nikitopoulou X, Vougas K, Townsend PA, Panayiotidis MI, et al. The DNA damage response and immune signaling alliance: Is it good or bad? Nature decides when and where. Pharmacol Ther. 2015;154:36\u201356.","journal-title":"Pharmacol Ther"},{"key":"3032_CR7","doi-asserted-by":"crossref","unstructured":"Lee ECY, Kok JST, Teh BT, Lim KS. Interplay between the DNA damage response and immunotherapy response in cancer. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms232113356"},{"key":"3032_CR8","first-page":"1","volume":"42","author":"P Nenclares","year":"2022","unstructured":"Nenclares P, Rullan A, Tam K, Dunn LA, St John M, Harrington KJ. Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations. Am Soc Clin Oncol Educ Book. 2022;42:1\u201316.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"3032_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931\u201347.","journal-title":"Nat Rev Drug Discov"},{"key":"3032_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.595361","volume":"11","author":"X Qiu","year":"2020","unstructured":"Qiu X, Hou QH, Shi QY, Jiang HX, Qin SY. Identification of hub prognosis-associated oxidative stress genes in pancreatic cancer using integrated bioinformatics analysis. Front Genet. 2020;11:595361.","journal-title":"Front Genet"},{"key":"3032_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oraloncology.2013.09.011","volume":"50","author":"SK Choudhari","year":"2014","unstructured":"Choudhari SK, Chaudhary M, Gadbail AR, Sharma A, Tekade S. Oxidative and antioxidative mechanisms in oral cancer and precancer: a review. Oral Oncol. 2014;50:10\u20138.","journal-title":"Oral Oncol"},{"key":"3032_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0027-5107(89)90197-8","volume":"214","author":"HF Stich","year":"1989","unstructured":"Stich HF, Anders F. The involvement of reactive oxygen species in oral cancers of betel quid\/tobacco chewers. Mutat Res. 1989;214:47\u201361.","journal-title":"Mutat Res"},{"key":"3032_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ni.3868","volume":"18","author":"T Maj","year":"2017","unstructured":"Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017;18:1332\u201341.","journal-title":"Nat Immunol"},{"key":"3032_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2467940","volume":"2017","author":"de Sa Junior","year":"2017","unstructured":"de Sa Junior, Camara PL, Porcacchia DAD, Fonseca AS, Jorge SD PMM, Araldi RP, et al. The roles of ROS in cancer heterogeneity and therapy. Oxid Med Cell Longev. 2017;2017:2467940.","journal-title":"Oxid Med Cell Longev"},{"key":"3032_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3032_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102329","volume":"106","author":"NI Vlachogiannis","year":"2020","unstructured":"Vlachogiannis NI, Gatsiou A, Silvestris DA, Stamatelopoulos K, Tektonidou MG, Gallo A, et al. Increased adenosine-to-inosine RNA editing in rheumatoid arthritis. J Autoimmun. 2020;106:102329.","journal-title":"J Autoimmun"},{"key":"3032_CR17","doi-asserted-by":"crossref","unstructured":"Sfikakis PP, Vlachogiannis NI, Ntouros PA, Mavrogeni S, Maris TG, Karantanas AH, et al. Microvasculopathy-related hemorrhagic tissue deposition of iron may contribute to fibrosis in systemic sclerosis: hypothesis-generating insights from the literature and preliminary findings. Life. 2022;12.","DOI":"10.3390\/life12030430"},{"key":"3032_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100075","volume":"6","author":"A Psyrri","year":"2021","unstructured":"Psyrri A, Gkotzamanidou M, Papaxoinis G, Krikoni L, Economopoulou P, Kotsantis I, et al. The DNA damage response network in the treatment of head and neck squamous cell carcinoma. ESMO Open. 2021;6:100075.","journal-title":"ESMO Open"},{"key":"3032_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1158\/2767-9764.CRC-22-0299","volume":"3","author":"N Gavrielatou","year":"2023","unstructured":"Gavrielatou N, Vathiotis I, Aung TN, Shafi S, Burela S, Fernandez AI, et al. Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma. Cancer Res Commun. 2023;3:558\u201363.","journal-title":"Cancer Res Commun"},{"key":"3032_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3892\/ijmm.2017.2903","volume":"39","author":"S Bai","year":"2017","unstructured":"Bai S, Feng Q, Pan XY, Zou H, Chen HB, Wang P, et al. Overexpression of wild-type p21Ras plays a prominent role in colorectal cancer. Int J Mol Med. 2017;39:861\u20138.","journal-title":"Int J Mol Med"},{"key":"3032_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.annonc.2023.12.011","volume":"35","author":"N Gavrielatou","year":"2024","unstructured":"Gavrielatou N, Fortis E, Spathis A, Anastasiou M, Economopoulou P, Foukas GRP, et al. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma. Ann Oncol. 2024;35:340\u201350.","journal-title":"Ann Oncol"},{"key":"3032_CR22","doi-asserted-by":"crossref","unstructured":"Souliotis VL, Vlachogiannis NI, Pappa M, Argyriou A, Ntouros PA, Sfikakis PP. DNA Damage response and oxidative stress in systemic autoimmunity. Int J Mol Sci. 2019;21.","DOI":"10.3390\/ijms21010055"},{"key":"3032_CR23","doi-asserted-by":"crossref","unstructured":"Economopoulou P, Anastasiou M, Papaxoinis G, Spathas N, Spathis A, Oikonomopoulos N, et al. Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with head and neck squamous cell carcinoma (HNSCC). Cancers. 2021;13.","DOI":"10.3390\/cancers13020286"},{"key":"3032_CR24","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","volume":"7","author":"KW Mouw","year":"2017","unstructured":"Mouw KW, Goldberg MS, Konstantinopoulos PA, D\u2019Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov. 2017;7:675\u201393.","journal-title":"Cancer Discov"},{"key":"3032_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/B978-0-12-387665-2.00006-7","volume":"110","author":"ML Hegde","year":"2012","unstructured":"Hegde ML, Izumi T, Mitra S. Oxidized base damage and single-strand break repair in mammalian genomes: role of disordered regions and posttranslational modifications in early enzymes. Prog Mol Biol Transl Sci. 2012;110:123\u201353.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"3032_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mrfmmm.2011.08.002","volume":"716","author":"T Sliwinski","year":"2011","unstructured":"Sliwinski T, Markiewicz L, Rusin P, Kabzinski J, Dziki L, Milonski J, et al. Impaired nucleotide excision repair pathway as a possible factor in pathogenesis of head and neck cancer. Mutat Res. 2011;716:51\u20138.","journal-title":"Mutat Res"},{"key":"3032_CR27","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-016-1081-3","volume":"18","author":"VL Souliotis","year":"2016","unstructured":"Souliotis VL, Vougas K, Gorgoulis VG, Sfikakis PP. Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus. Arthritis Res Ther. 2016;18:182.","journal-title":"Arthritis Res Ther"},{"key":"3032_CR28","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/blood-2007-05-089193","volume":"113","author":"MA Shammas","year":"2009","unstructured":"Shammas MA, Shmookler Reis RJ, Koley H, Batchu RB, Li C, Munshi NC. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood. 2009;113:2290\u20137.","journal-title":"Blood"},{"key":"3032_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0067-8","volume":"31","author":"JH Choudhury","year":"2014","unstructured":"Choudhury JH, Choudhury B, Kundu S, Ghosh SK. Combined effect of tobacco and DNA repair genes polymorphisms of XRCC1 and XRCC2 influence high risk of head and neck squamous cell carcinoma in northeast Indian population. Med Oncol. 2014;31:67.","journal-title":"Med Oncol"},{"key":"3032_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.yexmp.2010.08.005","volume":"89","author":"T Sliwinski","year":"2010","unstructured":"Sliwinski T, Walczak A, Przybylowska K, Rusin P, Pietruszewska W, Zielinska-Blizniewska H, et al. Polymorphisms of the XRCC3 C722T and the RAD51 G135C genes and the risk of head and neck cancer in a Polish population. Exp Mol Pathol. 2010;89:358\u201366.","journal-title":"Exp Mol Pathol"},{"key":"3032_CR31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"3032_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41419-021-03474-5","volume":"12","author":"M Raudenska","year":"2021","unstructured":"Raudenska M, Balvan J, Masarik M. Cell death in head and neck cancer pathogenesis and treatment. Cell Death Dis. 2021;12:192.","journal-title":"Cell Death Dis"},{"key":"3032_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108434","volume":"33","author":"E Pariset","year":"2020","unstructured":"Pariset E, Bertucci A, Petay M, Malkani S, Lopez Macha A, Paulino Lima IG, et al. DNA damage baseline predicts resilience to space radiation and radiotherapy. Cell Rep. 2020;33:108434.","journal-title":"Cell Rep"},{"key":"3032_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.558248","volume":"11","author":"BdLV Araujo","year":"2021","unstructured":"Araujo BdLV, Hansen M, Spanggaard I, Rohrberg K, Reker Hadrup S, Lassen U, et al. Immune cell profiling of peripheral blood as signature for response during checkpoint inhibition across cancer types. Front Oncol. 2021;11:558248.","journal-title":"Front Oncol"},{"key":"3032_CR35","doi-asserted-by":"publisher","first-page":"e20618","DOI":"10.1200\/JCO.2022.40.16_suppl.e20618","volume":"40","author":"L Zhang","year":"2022","unstructured":"Zhang L, Hou L, Wu J, Li C, Hu T, Zhu C, et al. Peripheral blood mononuclear cells (PBMCs), an ideal liquid biopsy approach to evaluate systematic immunity and predict response of neoadjuvant chemo-immunotherapy in resectable NSCLC. J Clin Oncol. 2022;40:e20618\u2013e.","journal-title":"J Clin Oncol"},{"key":"3032_CR36","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1084\/jem.20162115","volume":"214","author":"LJ Pallett","year":"2017","unstructured":"Pallett LJ, Davies J, Colbeck EJ, Robertson F, Hansi N, Easom NJW, et al. IL-2(high) tissue-resident T cells in the human liver: Sentinels for hepatotropic infection. J Exp Med. 2017;214:1567\u201380.","journal-title":"J Exp Med"},{"key":"3032_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07053-9","volume":"9","author":"J Smolders","year":"2018","unstructured":"Smolders J, Heutinck KM, Fransen NL, Remmerswaal EBM, Hombrink P, Ten Berge IJM, et al. Tissue-resident memory T cells populate the human brain. Nat Commun. 2018;9:4593.","journal-title":"Nat Commun"},{"key":"3032_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/discim\/kyad009","volume":"2","author":"SAP Colombo","year":"2023","unstructured":"Colombo SAP, Brown SL, Hepworth MR, Hankinson J, Granato F, Kitchen SJ, et al. Comparative phenotype of circulating versus tissue immune cells in human lung and blood compartments during health and disease. Discov Immunol. 2023;2:kyad009.","journal-title":"Discov Immunol"},{"key":"3032_CR39","doi-asserted-by":"crossref","unstructured":"Lucca LE, Axisa PP, Lu B, Harnett B, Jessel S, Zhang L, et al. Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells. J Exp Med. 2021;218.","DOI":"10.1084\/jem.20200921"},{"key":"3032_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/path.6197","volume":"261","author":"RS Vanguri","year":"2023","unstructured":"Vanguri RS, Smithy JW, Li Y, Zhuang M, Maher CA, Aleynick N, et al. Integration of peripheral blood- and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma. J Pathol. 2023;261:349\u201360.","journal-title":"J Pathol"},{"key":"3032_CR41","doi-asserted-by":"crossref","unstructured":"Milkovic L, Cipak Gasparovic A, Cindric M, Mouthuy PA. Short overview of ROS as cell function regulators and their implications in therapy concepts. Cells. 2019;8.","DOI":"10.3390\/cells8080793"},{"key":"3032_CR42","doi-asserted-by":"crossref","unstructured":"Van Loenhout J, Peeters M, Bogaerts A. Oxidative stress-inducing anticancer therapies: taking a closer look at their immunomodulating effects. Antioxidants. 2020;9.","DOI":"10.3390\/antiox9121188"},{"key":"3032_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2022.103409","volume":"120","author":"EM Barros","year":"2022","unstructured":"Barros EM, McIntosh SA, Savage KI. The DNA damage induced immune response: Implications for cancer therapy. DNA Repair. 2022;120:103409.","journal-title":"DNA Repair"},{"key":"3032_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2019.102673","volume":"83","author":"J Kay","year":"2019","unstructured":"Kay J, Thadhani E, Samson L, Engelward B. Inflammation-induced DNA damage, mutations and cancer. DNA Repair. 2019;83:102673.","journal-title":"DNA Repair"},{"key":"3032_CR45","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1007\/s00262-009-0671-1","volume":"58","author":"C Banissi","year":"2009","unstructured":"Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother. 2009;58:1627\u201334.","journal-title":"Cancer Immunol Immunother"},{"key":"3032_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"3032_CR47","doi-asserted-by":"publisher","first-page":"13587","DOI":"10.18632\/oncotarget.7277","volume":"7","author":"KC Strickland","year":"2016","unstructured":"Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7:13587\u201398.","journal-title":"Oncotarget"},{"key":"3032_CR48","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25:3753\u20138.","journal-title":"Clin Cancer Res"},{"key":"3032_CR49","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"27","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021;27:4685\u20139.","journal-title":"Clin Cancer Res"},{"key":"3032_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15315-8","volume":"11","author":"A Farkkila","year":"2020","unstructured":"Farkkila A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020;11:1459.","journal-title":"Nat Commun"},{"key":"3032_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 2020;38:489\u201399.e3.","journal-title":"Cancer Cell"},{"key":"3032_CR52","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. J Clin Oncol. 2018;36:1685\u201394.","journal-title":"J Clin Oncol"},{"key":"3032_CR53","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1200\/JCO.19.01021","volume":"37","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent\/persistent endometrial cancer. J Clin Oncol. 2019;37:2786\u201394.","journal-title":"J Clin Oncol"},{"key":"3032_CR54","doi-asserted-by":"crossref","unstructured":"Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, et al. Frameshift events predict anti-PD-1\/L1 response in head and neck cancer. JCI Insight. 2018;3.","DOI":"10.1172\/jci.insight.98811"},{"key":"3032_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105292","volume":"117","author":"M Moutafi","year":"2021","unstructured":"Moutafi M, Economopoulou P, Rimm D, Psyrri A. PARP inhibitors in head and neck cancer: molecular mechanisms, preclinical and clinical data. Oral Oncol. 2021;117:105292.","journal-title":"Oral Oncol"},{"key":"3032_CR56","doi-asserted-by":"crossref","unstructured":"Moutafi M, Koliou GA. Phase II window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer. Cancer Res Commun. 2023;3:1514\u201323.","DOI":"10.1158\/2767-9764.CRC-23-0051"},{"key":"3032_CR57","doi-asserted-by":"publisher","first-page":"TPS6125","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6125","volume":"42","author":"M Oliva","year":"2024","unstructured":"Oliva M, Llop S, Vidales Z, Arrazubi V, Baste N, Brana I, et al. TTCC-2022-01: Niraparib and dostarlimab in locally-advanced head and neck squamous cell carcinoma treated with (chemo) radiotherapy (RADIAN). J Clin Oncol. 2024;42:TPS6125\u2013TPS.","journal-title":"J Clin Oncol"},{"key":"3032_CR58","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, D\u00f3mine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non\u2013small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41:1992\u20138.","journal-title":"J Clin Oncol"},{"key":"3032_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","volume":"18","author":"LG Paz-Ares","year":"2023","unstructured":"Paz-Ares LG, Ciuleanu T-E, Cobo M, Bennouna J, Schenker M, Cheng Y, et al. First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations. J Thorac Oncol. 2023;18:204\u201322.","journal-title":"J Thorac Oncol"},{"key":"3032_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449\u201362.","journal-title":"N Engl J Med"},{"key":"3032_CR61","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330.","journal-title":"N Engl J Med"},{"key":"3032_CR62","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326.","journal-title":"N Engl J Med"},{"key":"3032_CR63","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"3032_CR64","doi-asserted-by":"crossref","unstructured":"Mayer ELGN, Leon-Ferre RA. TBCRC 056: a phase II study of neoadjuvant niraparib with dostarlimab for patients with BRCA- or PALB2-mutated breast cancer: results from the ER+\/HER2- cohort. In: Proceedings of the San Antonio Breast Cancer Symposium; San Antonio, TX, December 10\u201313, 2024 RF3-01.","DOI":"10.1158\/1557-3265.SABCS24-RF3-01"},{"key":"3032_CR65","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1200\/JCO.2024.42.16_suppl.5545","volume":"42","author":"K Harano","year":"2024","unstructured":"Harano K, Nakao T, Nishio S, Katsuta T, Tasaki K, Takehara K, et al. Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer. J Clin Oncol. 2024;42:5545.","journal-title":"J Clin Oncol"},{"key":"3032_CR66","doi-asserted-by":"publisher","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-18-1814","volume":"78","author":"Z Wang","year":"2018","unstructured":"Wang Z, Zhao J, Wang G, Zhang F, Zhang Z, Zhang F, et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 2018;78:6486\u201396.","journal-title":"Cancer Res"},{"key":"3032_CR67","doi-asserted-by":"crossref","unstructured":"Parkes EE, Walker SM, Taggart LE, McCabe N, Knight LA, Wilkinson R, et al. Activation of STING-dependent innate immune signaling By S-phase-specific DNA damage in breast cancer. J Natl Cancer Inst. 2017;109.","DOI":"10.1093\/jnci\/djw199"},{"key":"3032_CR68","doi-asserted-by":"crossref","unstructured":"Wang Y, Jiao X, Li S, Chen H, Wei X, Liu C, et al. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. Acta Pharm Sin B. 2021;19:1139\u201349.","DOI":"10.20892\/j.issn.2095-3941.2020.0708"},{"key":"3032_CR69","doi-asserted-by":"crossref","unstructured":"Heath O, Berlato C, Maniati E. Chemotherapy induces tumor-associated macrophages that aid adaptive immune responses in ovarian cancer. Cancer Immunol Res. 2021;9:665\u201381.","DOI":"10.1158\/2326-6066.CIR-20-0968"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03032-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03032-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T17:16:34Z","timestamp":1757178994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03032-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8,24]]}},"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03032-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,23]]},"assertion":[{"value":"28 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Amanda Psyrri has received honoraria and research funding from BMS, MSD, Roche, Pfizer, Merck Serono. AstraZeneca, Ipsen. She has also received research support from KURA Oncology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Ethical Committee of Attikon Hospital, Athens, Greece. All participants gave informed consent to participate in the study. The study was conducted according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}